The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...
The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...
Like most human traits, blue eyes are determined by genes, and no two people have exactly the same hue. It works a lot like ...
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
3D models provide a realistic environment for studying uveal melanoma They enable effective drug testing and personalized treatment approaches This research could lead to innovative therapies and ...
Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.
2d
Hosted on MSNImmunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?We expect investors to focus on the sales performance of Immunocore Holdings plc’s IMCR sole marketed drug, Kimmtrak ...
The updated NCCN Guidelines now include HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant uveal melanoma. Previously, the guidelines limited its use to patients with ...
Prognostic significance of pigmentation and stem cell markers in Indian population of uveal melanoma
Background Increased pigmentation has been associated with cancer stem-cell-like behaviour and chemoresistance in uveal ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results